Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of non-infectious intermediate, posterior or pan-uveitis~Exclusion Criteria:~* any ocular trauma within the past 6 months in the study eye~* any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study treatment, or any prior use of Retisert™ in the study eye~* any uncontrolled systemic disease that would preclude participation in the study or put the subject at risk due to study treatment or procedures~* have a known HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated~* are monocular~* have ocular hypertension~* history of any intraocular surgery in the study eye~* presence of an anterior staphyloma in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triamcinolone acetonide (Triesence®) (Type: EXPERIMENTAL): TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)

Based on this trial design, predict the completion outcome and termination type (if applicable).